

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 24. (canceled)

25. (previously presented) A method for treating a solid tumor comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

- i) an anti-human CXCR4 antibody, or a fragment thereof that binds to human CXCR4; and
- ii) an anti-human SDF-1 antibody, or a fragment thereof that binds to human SDF-1.

26. (previously presented) A method for treating a disease pathologically caused by neovascularization comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

- i) an anti-human CXCR4 antibody, or a fragment thereof that binds to human CXCR4; and
- ii) an anti-human SDF-1 antibody, or a fragment thereof that binds to human SDF-1.

27. (canceled)

28. (previously presented) A method for suppressing vascularization comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:

- i) an anti-human CXCR4 antibody, or a fragment thereof that binds to human CXCR4; and
- ii) an anti-human SDF-1 antibody, or a fragment thereof that binds to human SDF-1.

29. (canceled)

30. (canceled)